natgillin/translations-raw huggingface dataset:
Cain et al. ‘European Position Paper on Rhinosinusitis and Nasal Polyps' 2012; Update on the management of chronic rhinosinusitis. 
Cain idr., „European Position Paper on Rhinosinusitis and Nasal Polyps“ (Evropski dokument o stališču o rinosinuzitisu in nosnih polipih), 2012; Update on the management of chronic rhinosinusitis (Najnovejši podatki o obvladovanju kroničnega rinosinuzitisa), 2013; Infect Drug
According to the most recent guidelines4, the use of corticosteroids is recommended for mild-moderate rhinitis via intranasal route. 
Glede na najnovejše smernice4 je uporaba kortikosteroidov po intranazalni poti priporočljiva za blag ali zmeren rinitis.
The CHMP concluded that for asthma treatment no indication of duration of therapy should be reported in the SmPC; the duration of treatment should be based on clinical judgement on the basis on the severity and frequency of symptoms and patient conditions on a case-by-case basis. 
Odbor CHMP je sklenil, da v povzetku glavnih značilnosti zdravila ne sme biti navedena nobena indikacija za trajanje zdravljenja astme; trajanje zdravljenja mora temeljiti na klinični presoji glede na resnost in pogostnost simptomov in bolnikovih stanj za vsak primer posebej.
On review of all available data including post marketing safety data the CHMP concluded that a maximum of 3200 ug daily dose of BDP in adults and adolescents, which is in line with the current recommendation in Germany, Ireland and Greece and of a maximum of 1600 ug daily dose in children, which is in line with the current recommendation in France, is acceptable. 
CHMP sklenil, da sta dnevni odmerek BDP pri odraslih in mladostnikih, ki znaša največ 3 200 ug in je v skladu s trenutnim priporočilom v Nemčiji, na Irskem in v Grčiji, ter dnevni odmerek pri otrocih, ki znaša največ 1 600 ug in je v skladu s trenutnim priporočilom v Franciji, sprejemljiva.
Finally, recent evidence reports that distribution of topical solution to the unoperated sinuses is limited, with nebulization being also ineffective with <3% sinus penetration. 
Poleg tega najnovejši dokazi kažejo, da je porazdelitev raztopine za topikalno uporabo v neoperiranih sinusih omejena, pri čemer je neučinkovita tudi nebulizacija, saj je pri njej prodiranje v sinuse manjše od 3 %.
More importantly, ICS therapy is always patient-tailored and closely monitored by the physician in terms of symptom controls, thus precluding the occurring of prolonged unsatisfactory symptom control because of once-daily administration. 
Še pomembneje je, da je zdravljenje z IKS vedno prilagojeno posameznemu bolniku in ga z vidika nadzora nad simptomi skrbno spremlja zdravnik, zato zaradi dajanja enkrat dnevno ne more priti do dolgotrajnega nezadostnega nadzora nad simptomi.
In France nBDP is indicated as anti-inflammatory treatment of severe persistent asthma in children. 
V Franciji je zdravilo nBDP indicirano za protivnetno zdravljenje hude trajne astme pri otrocih.
For the recurrent wheezing indication in young children, the CHMP concluded that if no treatment benefit of is observed within 2-3 months, Clenil should be discontinued. 
Za indikacijo ponavljajočega se sopenja pri mlajših otrocih je odbor CHMP sklenil, da je treba zdravljenje z zdravilom Clenil prekiniti, če v obdobju od dveh do treh mesecev ni opaženih nobenih koristi zdravljenja.
The CHMP agreed with the indication "in the maintenance treatment of asthma" in line with the available scientific evidence and guideline recommendations where inhaled corticosteroids are considered the firstline treatment when a diagnosis of asthma has been done and nebulizers are recommended when the use of other hand-held inhalers is not appropriate. 
Odbor CHMP se je strinjal z indikacijo „za vzdrževalno zdravljenje astme“ v skladu z razpoložljivimi znanstvenimi dokazi in priporočili smernic, kadar po postavitvi diagnoze astme velja, da so inhalacijski kortikosteroidi prva izbira zdravljenja, nebulatorji pa so priporočeni, kadar uporaba drugih ročnih inhalatorjev ni ustrezna.
In Ireland, Germany and Greece nBDP is indicated in both adults and children for the treatment of bronchial asthma where use of a pressurised or dry powder inhaler is unsatisfactory or inappropriate. 
Na Irskem, v Nemčiji in v Grčiji je zdravilo nBDP indicirano za zdravljenje bronhialne astme pri odraslih in otrocih, kadar je uporaba inhalatorjev pod tlakom ali s praškom nezadovoljiva ali neustrezna.
Indeed, the CHMP noted that restricting the indication to only "asthma" might lead to an under-treatment of children < 5 years of age with recurrent wheezing without any other apparent risk factors for asthma. 
Odbor CHMP je dejansko ugotovil, da bi omejitev indikacije izključno na „astmo“ lahko vodila k pomanjkljivemu zdravljenju otrok, starih < 5 let, pri katerih se pojavlja ponavljajoče se sopenje, ne pa tudi drugi očitni dejavniki tveganja za astmo.
The evidence provided by the MAH in support of this indication consisted of 4 studies, only one of which is a randomised clinical trial (Profita et al., 2013)3. 
sestavljajo 4 študije, od katerih je le ena randomizirano klinično preskušanje (Profita idr., 2013)3.
In addition, the duration of treatment of recurrent wheezing should not exceed 3 months, unless diagnosis of asthma is confirmed to avoid an unnecessary long-term exposure. 
Poleg tega zaradi preprečevanja nepotrebne dolgotrajne izpostavljenosti zdravljenje ponavljajočega se sopenja ne sme trajati dlje od treh mesecev, razen če je potrjena diagnoza astme.
Other respiratory conditions with the narrowing of the airways in the lungs (bronchostenotic condition) 
Druge bolezni dihal, pri katerih so zožene dihalne poti v pljučih (stanje bronhostenoze)
The MAH stated that nebulisation is able to deliver drugs to paranasal sinuses while nasal sprays are not. 
Imetnik dovoljenja za promet z zdravilom je navedel, da lahko nebulizacija dovede zdravila v paranazalne sinuse, nosna pršila pa jih ne morejo.
Clenil is currently indicated for the treatment of other respiratory conditions with the narrowing of the airways in the lungs (bronchostenotic condition) in Italy. 
Zdravilo Clenil je v Italiji trenutno indicirano za zdravljenje drugih bolezni dihal, pri katerih so zožene dihalne poti v pljučih (stanje bronhostenoze).
Paediatric age range 
Starostni razpon pediatrične populacije
In GINA guideline, low dose ICS (controller treatment) is recommended as the preferred initial treatment to control asthma in children 5 years and younger. 
so IKS v nizkem odmerku (zdravljenje za nadzor bolezni) priporočljivi kot prednostno začetno zdravljenje za nadzor astme pri otrocih, starih do vključno 5 let.
In fact, pharmaceutical formulations for nebulization are intended for asthma treatment as they deliver particles with particle size distribution less than 5 microns that can reach lower airways using facial masks; the fact that a nebuliser suspension administered through the facial mask is not suitable for administration to the nasal cavity is also proven by the cited article by Profita and colleagues where no differences were observed between the nBDP provided by facial mask and the placebo group for symptom score of rhinitis. 
Pravzaprav so farmacevtske formulacije za nebulizacijo namenjene zdravljenju astme, saj zagotavljajo vnos delcev, katerih porazdelitev velikosti znaša manj kot 5 mikronov in ki lahko prek obraznih mask dosežejo spodnja dihala; dejstvo, da suspenzija za nebulator za dajanje prek obrazne maske ni primerna za dajanje v nosno votlino, je prav tako dokazano v citiranem članku avtorjev
• The committee reviewed the totality of the data submitted by the MAH in support of the proposed harmonisation of the product information. 
• odbor je pregledal vse podatke, ki jih je v podporo predlagani uskladitvi informacij o zdravilu predložil imetnik dovoljenja za promet z zdravilom;
As regards the indication in wheezing, the term “preschool” as proposed by the MAH was not considered as informative by the CHMP and not in line with the SmPC guideline. 
V zvezi z indikacijo za sopenje je odbor CHMP menil, da izraz „predšolski“, ki ga je predlagal imetnik dovoljenja za promet z zdravilom, ni informativen in ni v skladu s smernico o povzetku glavnih značilnosti zdravila.
The cumulative prevalence of wheeze is almost 50% at the age of 6 years. 
Skupna prevalenca sopenja pri starosti 6 let znaša skoraj
Sections 4.3 Contraindications to 5.3 Preclinical safety data have been harmonised to include the relevant available information, or amend wording according to the attest QRD template. 
Druga poglavja povzetka glavnih značilnosti zdravila Poglavja od poglavja 4.3 Kontraindikacije do poglavja 5.3 Predklinični podatki o varnosti so usklajena tako, da vključujejo ustrezne razpoložljive informacije ali pa je besedilo v njih spremenjeno v skladu z najnovejšo predlogo za pregled kakovosti dokumentov.
The evidence and argumentation provided by the MAH on the beneficial effect of nBDP in the treatment of the broad proposed indications (bronchostenotic condition as initial one, inflammatory disorders of the respiratory tract in particular associated with wheezing as second one) was considered by the CHMP unsatisfactory in identifying the medical need and the target population (lack of adequately designed and sized trials). 
Odbor CHMP je ocenil, da dokazi in utemeljitve koristi zdravila nBDP pri zdravljenju splošnih predlaganih indikacij (stanja bronhostenoze kot začetne indikacije ter vnetnih bolezni dihal, še posebno v povezavi s sopenjem, kot druge indikacije), ki jih je predložil imetnik dovoljenja za promet z zdravilom, nezadovoljivo prepoznavajo zdravstvene potrebe in ciljno populacijo (pomanjkanje ustrezno zasnovanih in ustrezno obsežnih preskušanj).
In conclusion, the CHMP considered that the available evidence does not support the proposed indications in "allergic and idiopathic rhinitis, inflammatory and allergic affections of the nasal cavities and of the rhino-pharyngeal tract" for nBDP. 
Sklepno mnenje odbora CHMP je bilo, da razpoložljivi dokazi ne podpirajo predlaganih indikacij zdravila nBDP za „alergijski in idiopatski rinitis ter vnetne in alergijske reakcije nosnih votlin in nosno-žrelnega predela“.
As such reference is not made to a brand rather to a “jet nebuliser” in the product information. 
Zato v informacijah o zdravilu ni sklicev na blagovno znamko, ampak na „nebulator na stisnjen zrak“.
Allergic and idiopathic rhinitis, inflammatory and allergic affections of the nasal cavities and of the rhinopharyngeal tract 
Alergijski in idiopatski rinitis, vnetne in alergijske reakcije nosnih votlin in nosno-žrelnega predela
In Italy nBDP is currently indicated in both adults and children for the treatment of asthma, and other respiratory conditions with the narrowing of the airways in the lungs (brochostenotic condition), specifically when the use of pressurised or dry powder inhalers is unsatisfactory or inappropriate. 
V Italiji je zdravilo nBDP trenutno indicirano za zdravljenje astme in drugih bolezni dihal, pri katerih so zožene dihalne poti v pljučih (stanja bronhostenoze), pri odraslih in otrocih, še posebno, kadar je uporaba inhalatorjev pod tlakom ali s praškom nezadovoljiva ali neustrezna.
2 Papi A. et al., ‘Regular vs prn nebulized treatment in wheeze preschool children'. 
idr., „Regular vs prn nebulized treatment in wheeze preschool children“ (Zdravljenje sopenja pri predšolskih otrocih: primerjava med običajnim zdravljenjem z nebulatorji in zdravljenjem z nebulatorji po potrebi).
The MAH proposed to revise the SmPC section 4.2 to include more detailed information on the nebuliser systems. 
Imetnik dovoljenja za promet z zdravilom je predlagal spremembo poglavja 4.2 povzetka glavnih značilnosti zdravila, da bi vključevalo podrobnejše informacije o nebulatorskih sistemih.
Section 1, (name of the medicial product) Sections 2 (qualitative and quantitative composition), 6.1 (list of excipients), and 6.2 (incompatibilities) have been updated with minor changes to be in line with QRD template. 
Poglavja 1 (Ime zdravila), 2 (Kakovostna in količinska sestava), 6.1 (Seznam pomožnih snovi) in 6.2
The nBDP indication in wheezing would allow paediatricians to treat young children suffering from recurring wheezing when a clear asthma diagnosis is not achievable, in line with GINA guideline1. 
Pediatrom bi v skladu s smernico GINA1 indikacija zdravila nBDP za sopenje omogočala zdravljenje mlajših otrok, pri katerih se pojavlja ponavljajoče se sopenje, kadar jasne diagnoze astme ni mogoče postaviti.
• the product information proposed by the Marketing Authorisation Holders has been assessed based on the documentation submitted and the scientific discussion within the Committee, 
• odbor je na podlagi predložene dokumentacije in znanstvene razprave v odboru ocenil informacije o zdravilu, ki so jih predlagali imetniki dovoljenj za promet z zdravili;
Beclometasone dipropionate exerts local anti-inflammatory action in the control of bronchial asthma. 
Beklometazon dipropionat pri nadzoru bronhialne astme deluje lokalno protivnetno.
nBDP is also indicated in allergic and idiopathic rhinitis, inflammatory and allergic affections of the nasal cavities and of the rhino-pharyngeal tract. 
Zdravilo nBDP je indicirano tudi pri alergijskem in idiopatskem rinitisu ter vnetnih in alergijskih reakcijah nosnih votlin in nosno-žrelnega predela.
4 Allergic Rhinitis and its Impact on Asthma (ARIA) guideline 2015: Available from http://www.whiar.org/Documents&Resources.php 
Smernica za alergijski rinitis in njegov vpliv na astmo (Allergic Rhinitis and its Impact on Asthma - ARIA), 2015.
The package leaflet has been amended to reflect the changes of the SmPC 
Navodilo za uporabo je spremenjeno tako, da izraža spremembe povzetka glavnih značilnosti zdravila.
Profita M. et al ‘ Effect of Nebulized Beclomethasone on Airway Inflammation and Clinical Status of Children with Allergic Asthma and Rhinitis: A Randomized, Double-Blind, Placebo-Controlled Study'. 
otrok z alergijsko astmo in rinitisom: randomizirana, dvojno slepa, s placebom nadzorovana študija).
The Netherlands ratiopharm Nederland bv 
Nizozemska ratiopharm Nederland bv
CC Zaandam, The 
CC Zaandam,
POSSIBLE SIDE EFFECTS Like all medicines, Fentanyl-ratiopharm can cause side effects, although not everybody gets them. 
MOŽNI NEŽELENI UČINKI Kot vsa zdravila imajo lahko tudi obliži Fentanyl-ratiopharm neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
- asthma, respiratory depression or any lung disease - low blood pressure - impaired liver function - impaired kidney function - if you have had a head injury, a brain tumour, signs of increased intracranial pressure (e.g. 
- astma, depresija dihanja ali katero koli bolezen pljuč - nizek krvni tlak - okvarjeno delovanje jeter - okvarjeno delovanje ledvic - če ste imeli poškodovano glavo, možganski tumor ali znake povišanega intrakranialnega tlaka
6.4 Special precautions for storage 
Posebna navodila za shranjevanje
the CHMP has recommended the granting of the Marketing Authorisation(s) and the amendment of the Summary of Product Characteristics, labelling and package leaflet which are set out in Annex III for Fentanyl-ratiopharm and associated names (see Annex I). 
CHMP priporočil podelitev dovoljenj(a) za promet in dopolnitev povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo, kot je podano v Dodatku III za zdravilo Fentanylratiopharm in z njim povezana imena (glejte Dodatek I).
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF FENTANYLRATIOPHARM AND ASSOCIATED NAMES (SEE ANNEX I) 
SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA FENTANYLRATIOPHARM IN Z NJIM POVEZANIH IMEN (GLEJTE DODATEK I)
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, 
- Če katerikoli neželeni učinek postane resen ali, če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
Fentanyl ratiopharm 100 µg/h, dispositif transdermique The Netherlands Fentanyl ratiopharm 100 µg/uur, pleister voor transdermaal gebruik United Kingdom Telfanyl 100 microgram/hr Transdermal patch 
Fentanyl ratiopharm 100 µg/uur, pleister voor transdermaal gebruik Velika Britanija Telfanyl 100 microgram/hr Transdermal patch
Fentanyl ratiopharm 75 µg/h, dispositif transdermique The Netherlands Fentanyl ratiopharm 75 µg/uur, pleister voor transdermaal gebruik United Kingdom Telfanyl 75 microgram/hr Transdermal patch 
Fentanyl ratiopharm 75 µg/uur, pleister voor transdermaal gebruik Velika Britanija Telfanyl 75 microgram/hr Transdermal patch
Telfanyl 100 microgram/hr Transdermal patch (pending) 
Telfanyl 100 microgram/hr Transdermal patch (v obravnavi)
Fentanyl ratiopharm 25 µg/h, dispositif transdermique The Netherlands Fentanyl ratiopharm 25 µg/uur, pleister voor transdermaal gebruik United Kingdom Telfanyl 25 microgram/hr Transdermal patch 
Fentanyl ratiopharm 25 µg/uur, pleister voor transdermaal gebruik Velika Britanija Telfanyl 25 microgram/hr Transdermal patch
Telfanyl 75 microgram/hr Transdermal patch (pending) 
Telfanyl 75 microgram/hr Transdermal patch (v obravnavi)
Fentanyl ratiopharm 50 µg/h, dispositif transdermique The Netherlands Fentanyl ratiopharm 50 µg/uur, pleister voor transdermaal gebruik United Kingdom Telfanyl 50 microgram/hr Transdermal patch 
Fentanyl ratiopharm 50 µg/uur, pleister voor transdermaal gebruik Velika Britanija Telfanyl 50 microgram/hr Transdermal patch
Telfanyl 25 microgram/hr Transdermal patch (pending) 
Telfanyl 25 microgram/hr Transdermal patch (v obravnavi)
Telfanyl 50 microgram/hr Transdermal patch (pending) 
Telfanyl 50 microgram/hr Transdermal patch (v obravnavi)
Fentanyl-ratiopharm 100 µg/h Matrixpflaster and associated names (see Annex I) 
Fentanyl-ratiopharm 100 µg/h Matrixpflaster in povezana imena (glejte dodatek I) [Glejte dodatek I - Izpolni država članica]
Fentanyl-ratiopharm 75 µg/h Matrixpflaster and associated names (see Annex I) 
Fentanyl-ratiopharm 75 µg/h Matrixpflaster in povezana imena (glejte dodatek I) [Glejte dodatek I - Izpolni država članica]
NAME OF THE MEDICINAL PRODUCT Fentanyl-ratiopharm 100 µg/h Matrixpflaster and associated names (see Annex I) [See Annex I - To be completed nationally] fentanyl 
NAVODILO ZA UPORABO Fentanyl-ratiopharm 100 µg/h Matrixpflaster in povezana imena (glejte dodatek I) [Glejte Dodatek I - Izpolni država članica] fentanil
50 µg/h transdermal patch transdermal use 8.25 mg/15 cm² which release 50 µg fentanyl per hour 
Graf-Arco-Str. 3 89079 Ulm Nemčija ratiopharm 50 µg/h, dispositif transdermique obliž uporaba površina: 15 cm2) vsebuje 8,25 mg fentanila (ustreza hitrosti sproščanja učinkovine 50 mikrogramov/h).
Fentanyl-ratiopharm 50 µg/h Matrixpflaster and associated names (see Annex I) 
Fentanyl-ratiopharm 50 µg/h Matrixpflaster in povezana imena (glejte dodatek I) [Glejte dodatek I - Izpolni država članica]
NAME OF THE MEDICINAL PRODUCT Fentanyl-ratiopharm 25 µg/h Matrixpflaster and associated names (see Annex I) [See Annex I - To be completed nationally] 
Fentanyl-ratiopharm 25 µg/h Matrixpflaster in povezana imena (glejte dodatek I) [Glejte dodatek I - Izpolni država članica]
NAME OF THE MEDICINAL PRODUCT Fentanyl-ratiopharm 75 µg/h Matrixpflaster and associated names (see Annex I) [See Annex I - To be completed nationally] fentanyl 
Fentanyl-ratiopharm 75 µg/h Matrixpflaster in povezana imena (glejte dodatek I) [Glejte Dodatek I - Izpolni država članica] fentanil
NAME OF THE MEDICINAL PRODUCT Fentanyl-ratiopharm 25 µg/h Matrixpflaster and associated names (see Annex I) [See Annex I - To be completed nationally] fentanyl 
Fentanyl-ratiopharm 25 µg/h Matrixpflaster in povezana imena (glejte dodatek I) [Glejte Dodatek I - Izpolni država članica] fentanil
Albert-SchweitzerGasse 3, 1140 WIEN, Austria transdermales Matrixpflaster 
Albert-SchweitzerGasse 3, 1140 WIEN, Avstrija µg/h transdermales Matrixpflaster vsebuje 4,125 mg fentanila (ustreza hitrosti sproščanja učinkovine 25 mikrogramov/h)
NAME OF THE MEDICINAL PRODUCT Fentanyl-ratiopharm 50 µg/h Matrixpflaster and associated names (see Annex I) [See Annex I - To be completed nationally] fentanyl 
Fentanyl-ratiopharm 50 µg/h Matrixpflaster in povezana imena (glejte dodatek I) [Glejte dodatek I - Izpolni država članica] fentanil
Primary prevention 
Primarna preventiva
This was not observed in the aforementioned subgroup of patients with dyslipidaemia but there was also no clear evidence of benefit in dyslipidaemic women treated with fenofibrate plus simvastatin, and a possible harmful effect in this subgroup could not be excluded. 
Tega niso opazili v prej omenjenih podskupinah bolnikov z dislipidemijo, izostali pa so tudi jasni dokazi koristi pri ženskah z dislipidemijo, zdravljenih s fenofibratom in simvastatinom, pa tudi možnosti neželenih učinkov v teh podskupinah ni mogoče izključiti.
[Product name] belongs to a group of medicines commonly known as fibrates. 
Zdravilo [Ime zdravila] spada v skupino zdravil, imenovanih fibrati.
After one year, the mean HDL-C level was 6% higher and the mean triglyceride level was 31% lower in the gemfibrozil group than in the placebo group. 
Po enem letu je bila pri skupini z gemfibrozilom srednja vrednost HDL holesterola 6% višja, srednja vrednost trigliceridov pa 31% nižja v primerjavi s skupino s placebom.
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) lipid trial was a randomized placebocontrolled study of 5518 patients with type 2 diabetes mellitus treated with fenofibrate in addition to simvastatin. 
Preskušanje maščob v okviru preskušanja ACCORD (Action to Control Cardiovascular Risk in DiabetesACCORD) je bila randomizirana, s placebom kontrolirana študija pri 5.518 bolnikih s sladkorno boleznijo tipa 2, ki so bili poleg simvastatina dodatno zdravljeni s fenofibratom.
[Product name] may also be prescribed to people who cannot be prescribed other lipid-lowering medicines for lowering blood cholesterol levels. 
[Ime izdelka] se lahko predpiše tudi ljudem, katerim ne moremo predpisati drugih zdravil za znižanje vrednosti holesterola v krvi.
- Mixed hyperlipidaemia in patients at high cardiovascular risk in addition to a statin when triglycerides and HDL cholesterol are not adequately controlled. 
- mešana hiperlipidemija pri bolnikih z visokim tveganjem za kardiovaskularne dogodke dodatno k zdravljenju s statinu, kadar trigliceridi in holesterol HDL niso pod ustreznim nadzorom.
Another prespecified subgroup analysis identified a statistically significant treatment-by-gender interaction (p = 0.01) indicating a possible treatment benefit of combination therapy in men (p=0.037) but a potentially higher risk for the primary outcome in women treated with combination therapy compared to simvastatin monotherapy (p=0.069). 
Analiza druge predhodno označene podskupine, opredeljene kot statistično značilna interakcija zdravljenja za spol (p = 0,01), kaže na možne koristi zdravljenja s kombinirano terapijo za moške (p = 0,037), a potencialno večje tveganje za primarni izid pri ženskah, zdravljenih s kombinirano terapijo v primerjavi s simvastatinom v monoterapiji (p = 0,069).
There is evidence that treatment with fibrates may reduce coronary heart disease events but they have not been shown to decrease all cause mortality in the primary or secondary prevention of cardiovascular disease. 
Obstajajo dokazi, da zdravljenje s fibrati lahko zmanjša dogodke povezane s koronarno boleznijo srca, ni pa dokazov, da fibrati zmanjšajo umrljivost zaradi vseh vzrokov pri primarni ali sekundarni preventivi kardiovaskularnih bolezni.
The VA-HIT study was a double-blind study comparing gemfibrozil (1200 mg per day) with placebo in 2531 men with a history of coronary heart disease, HDL-C levels of < 40 mg/dL (1.0 mmol/L), and normal LDL C levels. 
Z dvojno slepo študijo VA-HIT so primerjali učinek gemfibrozila (1200 mg na dan) s placebom pri 2531 moških z anamnezo koronarne srčne bolezni, z vrednostjo HDL holesterola < 40 mg/dL (1,0 mmol/L) in z normalnimi vrednostmi LDL holesterola.